Literature DB >> 8251323

Hyperlipidemia in childhood nephrotic syndrome.

M A Thabet1, J R Salcedo, J C Chan.   

Abstract

Hyperlipidemia is an important characteristic of nephrotic syndrome (NS). Elevation of plasma total cholesterol, or more specifically low-density lipoprotein cholesterol, is the major lipid abnormality in NS, although hypertriglyceridemia may develop as the disorder progresses. The pathophysiology of nephrotic hyperlipidemia is complex. The prevailing view is that both hepatic synthesis of lipids and of apolipoproteins is increased, and that the clearance of chylomicrons and very low-density lipoproteins is reduced. The precise contribution of increased lipogenesis and decreased lipid catabolism to hyperlipidemia, and their relationship to urinary protein loss, hypoalbuminemia and reduced serum oncotic pressure remain controversial. There are two potential risks of elevated plasma lipids: atherosclerosis and progression of glomerular injury. Although neither of these complications has been proved with certainty, there is growing evidence that both may be long-term consequences of NS. Therefore, the diagnosis and treatment of lipid abnormalities, important aspects of the management of nephrotic children, is summarized here to provide pediatric nephrologists with an informed choice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8251323     DOI: 10.1007/bf00852550

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  84 in total

1.  Metabolic channeling in experimental nephrosis. II. Lipide metabolism.

Authors:  J B MARSH; D L DRABKIN
Journal:  J Biol Chem       Date:  1955-02       Impact factor: 5.157

2.  Studies on the synthesis and secretion of serum lipoproteins by rat liver slices.

Authors:  C M RADDING; D STEINBERG
Journal:  J Clin Invest       Date:  1960-10       Impact factor: 14.808

Review 3.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

4.  Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.

Authors:  B L Kasiske; M P O'Donnell; W J Garvis; W F Keane
Journal:  Circ Res       Date:  1988-02       Impact factor: 17.367

5.  Ischaemic heart-disease as a complication of nephrotic syndrome.

Authors:  G M Berlyne; N P Mallick
Journal:  Lancet       Date:  1969-08-23       Impact factor: 79.321

6.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

Review 7.  Pathogenesis and management of lipoprotein disorders.

Authors:  E J Schaefer; R I Levy
Journal:  N Engl J Med       Date:  1985-05-16       Impact factor: 91.245

8.  Regulation of bile acid synthesis. V. Inhibition of conversion of 7-dehydrocholesterol to cholesterol is associated with down-regulation of cholesterol 7 alpha-hydroxylase activity and inhibition of bile acid synthesis.

Authors:  W M Pandak; Z R Vlahcevic; D M Heuman; P B Hylemon
Journal:  J Lipid Res       Date:  1990-12       Impact factor: 5.922

9.  Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol.

Authors:  G L Vega; S M Grundy
Journal:  JAMA       Date:  1987-01-02       Impact factor: 56.272

10.  High density lipoproteinuria in nephrotic syndrome.

Authors:  S G de Mendoza; M L Kashyap; C Y Chen; R F Lutmer
Journal:  Metabolism       Date:  1976-10       Impact factor: 8.694

View more
  7 in total

1.  Paraoxonase 1 192 and 55 polymorphisms in nephrotic children.

Authors:  Nese Karaaslan Biyikli; Harika Alpay; Nurdan Yildiz; Bedia Agachan; Arzu Ergen; Umit Zeybek; Nilufer Bozkurt; Turgay Ispir
Journal:  Pediatr Nephrol       Date:  2006-03-26       Impact factor: 3.714

2.  Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome.

Authors:  Peng Hu; Yuan Han Qin; Cheng Xue Jing; Feng Ying Lei; Ping Chen; Ming Fang Li
Journal:  Mol Biol Rep       Date:  2008-05-30       Impact factor: 2.316

3.  Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome.

Authors:  Maria H Kniazewska; Anna K Obuchowicz; Tomasz Wielkoszyński; Joanna Zmudzińska-Kitczak; Katarzyna Urban; Marta Marek; Jolanta Witanowska; Karolina Sieroń-Stołtny
Journal:  Pediatr Nephrol       Date:  2008-10-30       Impact factor: 3.714

4.  Genetic variation of apolipoprotein E does not contribute to the lipid abnormalities secondary to childhood minimal change nephrotic syndrome.

Authors:  Peng Hu; Yuan Han Qin; Ling Lu; Bo Hu; Cheng Xue Jing; Feng Ying Lei; Ming Fang Li
Journal:  Int Urol Nephrol       Date:  2009-02-25       Impact factor: 2.370

5.  CD36 Mediated Fatty Acid-Induced Podocyte Apoptosis via Oxidative Stress.

Authors:  Wei Hua; Hui-zhe Huang; Lan-ting Tan; Jiang-min Wan; Hai-bo Gui; Liang Zhao; Xiong-zhong Ruan; Xue-mei Chen; Xiao-gang Du
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

6.  Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome.

Authors:  Lagu He; Pengfei Wu; Li Tan; Bai Le; Wenhan Du; Ting Shen; Jiali Wu; Zheyi Xiang; Min Hu
Journal:  Lipids Health Dis       Date:  2017-09-06       Impact factor: 3.876

7.  Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).

Authors:  Ayaka Domon; Kentaro Katayama; Touko Sato; Yuki Tochigi; Hiroyuki Tazaki; Hiroetsu Suzuki
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.